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Abstract
Background: The variable efficacy (0–80%) of Mycobacterium bovis Bacille Calmette Gure ´in (BCG) vaccine against adult
tuberculosis (TB) necessitates development of alternative vaccine candidates. Development of recombinant BCG (rBCG)
over-expressing promising immunodominant antigens of M. tuberculosis represents one of the potential approaches for the
development of vaccines against TB.
Methods/Principal Findings: A recombinant strain of BCG - rBCG85C, over expressing the antigen 85C, a secretory immuno-
dominant protein of M. tuberculosis, was evaluated for its protective efficacy in guinea pigs against M. tuberculosis challenge
by aerosol route. Immunization with rBCG85C resulted in a substantial reduction in the lung (1.87 log10, p,0.01) and spleen
(2.36 log10, p,0.001) bacillary load with a commensurate reduction in pathological damage, when compared to the animals
immunized with the parent BCG strain at 10 weeks post-infection. rBCG85C continued to provide superior protection over
BCG even when post-challenge period was prolonged to 16 weeks. The cytokine profile of pulmonary granulomas revealed
that the superior protection imparted by rBCG85C was associated with the reduced levels of pro-inflammatory cytokines -
interleukin (IL)-12, interferon (IFN)-c, tumor necrosis factor (TNF)-a, moderate levels of anti-inflammatory cytokine -
transforming growth factor (TGF)-b along with up-regulation of inducible nitric oxide synthase (iNOS). In addition, the
rBCG85C vaccine induced modulation of the cytokine levels was found to be associated with reduced fibrosis and antigen
load accompanied by the restoration of normal lung architecture.
Conclusions/Significance: These results clearly indicate the superiority of rBCG85C over BCG as a promising prophylactic
vaccine against TB. The enduring protection observed in this study gives enough reason to postulate that if an open-ended
study is carried out with low dose of infection, rBCG85C vaccine in all likelihood would show enhanced survival of guinea pigs.
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Introduction
Mycobacterium tuberculosis continues to be a leading cause of
human deaths due to an infectious agent [1]. The situation has
become even more precarious due to the emergence of multi drug
resistant strains of M. tuberculosis and lethal combination of
tuberculosis (TB) and HIV infections [2,3]. It has been
indisputably accepted by TB experts that complete eradication
of this disease may be difficult to achieve without the availability of
an efficient vaccine. Mycobacterium bovis Bacille Calmette Gure ´in
(BCG), the only vaccine currently in use against TB, despite its
satisfactory performance against childhood TB, does not impart
adequate protection against pulmonary TB in adults, with its
efficacy ranging from 0–80% [4,5,6].
Development of recombinant BCG (rBCG) based vaccines
over-expressing promising immuno-dominant antigens of M.
tuberculosis represents one of the potential approaches to improve
upon the performance of BCG [7,8,9,10]. The proteins belonging
to the antigen 85 (Ag85) complex, a family of 30–32 kDa proteins
(Ag85A, Ag85B and Ag85C) represent a group of the major
secretory and immunodominant proteins of M. bovis BCG and M.
tuberculosis [11,12] leading to their inclusion in several approaches
for the development of vaccines against TB [13,14,15,16]. Of the
three members of the Ag85 complex, Ag85C (fbpC, Rv0129c), in
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activity of M. tuberculosis and is singularly responsible for almost
40% mycolate content of this pathogen [17,18]. The mycolyl
transferase activity specific to Ag85C cannot be substituted by the
other two members i.e. Ag85A and 85B as shown by the reduction
in the mycolic acid content in the mutant of M. tuberculosis lacking
Ag85C activity [18,19]. In addition to its role in cell wall
biosynthesis, it has also been shown to be highly immuno-
dominant in nature, with several epitopes recognized by CD4 and
CD8 T cells [20,21,22]. In addition, a preferential recognition of
Ag85C over the other two members of the Ag85 complex, by sera
obtained from childhood TB patients especially by the smear and
culture negative patients, further signifies its immunodominant
nature [23]. Moreover, gene encoding Ag85C is known to be up-
regulated in the activated macrophages infected with M.
tuberculosis, perhaps allowing the bacilli to thicken its cell wall in
order to resist the onslaught of the bactericidal mechanisms of the
host [24]. The extra-cellular abundance of Ag85C and its
immunodominant nature makes this antigen an attractive target
for the development of anti-TB vaccines. We have earlier reported
the construction of rBCG strains over-expressing the immuno-
dominant antigens of Ag85 complex under the transcriptional
control of mycobacterial promoters of varying strength [25]. The
immunogenicity of some of these rBCG strains was also studied in
murine model [14,26]. In the present study, the protective efficacy
of rBCG85C was assessed in a highly susceptible guinea pig model
along with the evaluation of immune responses following M.
tuberculosis challenge by the aerosol route. Immunization of guinea
pigs with rBCG85C resulted in a significantly enhanced protection
characterized by a marked reduction in bacillary load in lungs and
spleen along with a significantly reduced pathology in various
organs, when compared to BCG immunization, at least up to 16
weeks post-infection.
Furthermore, in order to gain an insight into the immunological
basis of protection and disease-associated pathology, expression of
cytokines and presence of mycobacterial antigens were measured
in pulmonary granulomatous lesions by immunohistochemistry
(IHC). In addition, semi-quantitative real time PCR (qPCR) for
various cytokines (IL-12, IFN-c, TNF-a and TGF-b) and inducible
nitric oxide synthase (iNOS) was also performed on the total RNA
isolated from lung tissues. Analysis of various immuno-patholog-
ical parameters that influence protective efficacy demonstrated
that rBCG85C vaccine induced modulation of the cytokine levels
was associated with the reduced bacillary and antigen load
accompanied by the restoration of normal lung architecture.
Materials and Methods
Bacteria
M. bovis BCG (Danish strain) was procured from BCG
laboratories, Chennai, India. M. tuberculosis H37Rv was kindly
provided by Dr. J. S. Tyagi, All India institute of medical sciences,
New Delhi, India. BCG, rBCG85C and M. tuberculosis strains were
grown to mid-log phase in Middle Brook (MB) 7H9 media and
stocks were prepared as described earlier [27].
Preparation of antigens for immunization
For preparation of rBCG85C, a Mycobacteria - Escherichia coli shuttle
plasmid pSD5.pro was used as described earlier [25,28]. Briefly, the
plasmid (pSD5.pro) was engineered to over-express Ag85C along
with its native signal sequence under transcriptional control of the
promoter of M. leprae gene encoding heat shock protein 65 (hsp65).
The plasmid was electroporated into M. bovis BCG and selected on
MB7H11 plates containing Kanamycin (25 mg/ml).
Experimental animals
Pathogen free 200–300 g female outbred guinea pigs (Dunkin
Hartley strain) used for the protective efficacy studies were
procured from Disease Free Small Animal House Facility,
Haryana Agricultural University, Hissar, India. The animals were
housed in stainless steel cages and were provided with ad libitum
food and water in a BSLIII facility (National JALMA Institute of
Leprosy and Other Mycobacterial Diseases, Agra, India). All the
experimental protocols were reviewed and approved by the animal
ethics committee of the institute.
Immunization and aerosol challenge of guinea pigs with
M. tuberculosis
For evaluation of protective efficacy, two experiments were
carried out by varying the interval between (i) immunization and
infection and (ii) infection and euthanasia. In each experiment,
guinea pigs (n=6) were immunized with 5610
5 CFU of either
BCG (Danish strain) or rBCG85C in 100 ml of saline by intra-
dermal (i.d.) route. In the control group, guinea pigs were injected
with 100 ml of saline (i.d.).
In Exp-I, guinea pigs were challenged 6 weeks post immuni-
zation with ,500 bacilli of virulent M. tuberculosis H37Rv via the
respiratory route in an aerosol chamber (Inhalation exposure
system, Glasscol Inc., IN, USA) and were euthanized 10 weeks
following the infection. In Exp-II, the time interval between
immunization and challenge was extended to 12 weeks and
animals were euthanized 16 weeks post infection.
Measurement of protective efficacy
Animals were monitored regularly for change in body weight
and general body condition as an indicator of disease progression
and were euthanized at specified time points. In addition to the
measurement of bacillary load in lung and spleen, gross and
histopathological changes in various organs and extent of
pulmonary fibrosis were evaluated. A significant reduction in
these parameters in vaccinated animals was considered as a
protective effect of the vaccine.
Necropsy procedure and gross pathological evaluation
Guinea pigs were euthanized by i.p. injection of Thiopentone
sodium (100 mg/kg body weight) (Neon Laboratories Ltd., India).
After aseptically dissecting the animals, lung, liver and spleen were
examined for gross pathological changes and scored using the
Mitchison scoring system [29] with minor modifications (Table
S1), wherein equal emphasis was given to each organ. For
histopathological evaluation, three lung lobes (right caudal, middle
and cranial) and a portion of left dorsal lobe of liver were removed
and fixed in 10% neutral buffered formalin. Left caudal lung lobe
and cranial portion of spleen were aseptically removed for the
measurement of bacillary load. A portion of left cranial lung lobe
and caudal portion of spleen were stored in RNA laterH (Ambion,
TX, USA) at 220uC for isolation of RNA to be used for real time
RT-PCR studies.
Bacterial enumeration
Specific portions of lungs and spleen were weighed and
homogenized separately in 5 ml saline in a Teflon glass
homogenizer. Appropriate dilutions of the homogenates were
inoculated on to MB7H11 agar plates in duplicates and incubated
at 37uCi naC O 2 incubator for three to four weeks. The number
of colonies were counted and expressed as log10 CFU/g of tissue.
The detection limit in case of both lung and spleen CFU was 1.0
log10 CFU/g.
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Sections of 5 mm thickness from formalin fixed and paraffin
embedded tissues were cut on to glass slides and stained with
haematoxylin and eosin for histo-pathological examination. The
percent granuloma in lung and liver, type and extent of necrosis,
organization of granuloma along with the type of infiltrating cells
were assessed as described earlier [30]. In order to determine the
extent of collagen deposition and fibrosis, the lung sections were
also stained with Van Gieson stain.
Immunohistochemistry
Deparaffinized and re-hydrated lung sections were quenched
for endogenous peroxidase with 3% hydrogen peroxide (in
methanol) followed by antigen retrieval at 90–100uC for 10 min
in citrate buffer (pH-6.5). After blocking the non-specific sites with
2% BSA and 4% goat sera in PBS, sections were probed with
rabbit polyclonal anti-sera against guinea pig IFN-c, TNF-a
(kindly provided by Dr. DN McMurray, The Texas A&M
University System Health Science Center, TX, USA) and Ag85
complex of M. tuberculosis (raised in our laboratory) overnight at
4uC. Following washing with PBST (containing 0.1% Triton-
6100 and 0.5% BSA) and PBS three times, sections were treated
with horseradish peroxidase (HRP) conjugated goat anti-rabbit
antiserum (Jackson laboratories, PA, USA). Finally, the antibody
bound antigenic sites were detected by a colored reaction (brown)
using diaminobenzedine as a chromogenic substrate for HRP and
the slides were counterstained with Mayer’s haematoxylin.
Negative controls were treated with similar procedure except that
primary antibody was replaced with normal rabbit sera.
Image analysis
The tissue sections were examined by light microscopy and the
images were captured by using a CCD camera DS-Fi1-U2 (Nikon
Corp., Tokyo, Japan). The whole section was examined to
determine area and intensity of staining. Immuno-reactivity was
manually scored by estimating the area showing characteristic
staining (A, 1=,10%, 2=10–25%, 3=25–50%, 4=.50%) and
by estimating the intensity of staining (I, 1=weak, 2=moderate,
3=strong, 4=very strong). A quick score (Q) was calculated for
each slide by the formula (Q=A6I). The quick score values were
categorized as low (1–2), moderate (3–6) and high (8–16).
RNA extraction and real time RT-PCR
Total RNA was isolated from lung tissues using RNeasy mini
columns and contaminating genomic DNA was removed by on
column treatment with RNase free DNase (Qiagen Inc, CA,
USA). Approximately 3 mg of total RNA from each animal was
reverse transcribed by using random hexamers and Omniscript
RT kit (Qiagen Inc, CA, USA) as per the manufacturer’s
instructions. Primers for guinea pig IFN-c, TNF-a, TGF-b and
IL-12 were designed with Primer Express software (Applied
Biosystems, CA, USA) by using cDNA sequences available in the
public database (http://www. ncbi.nlm.nih.gov) (Table S2).
Primers for iNOS and 18S rRNA were used as described earlier
[31,32]. Real time PCR was performed by using SYBR green
PCR Master Mix (Applied Biosystems, CA, USA) as per the
manufacturer’s instructions.
Statistical analysis
Mean differences for Log10 CFU and % fold induction in
mRNA expression levels as measured by real time PCR were
analyzed by one-way analysis of variance (ANOVA). Least square
difference and Duncan’s post hoc tests were also carried out to
determine the significance of differences between various groups.
The differences between scores allotted for gross pathological
lesions, granuloma percent, quick score (Q) for IHC and extent of
collagen deposition across different groups were analysed by non-
parametric methods. The non-parametric Kruskal-Wallis test was
employed for comparison of multiple groups, followed by the
Mann-Whitney U test for comparison between two groups. The
differences were considered statistically significant when the p
values were less than 0.05. These statistical tests were run on SPSS
software (Version. 10.0, SPSS Inc., Illinois, USA).
Results
rBCG85C vaccination limits bacillary multiplication
To evaluate the efficacy of rBCG85C vaccination, following an
aerosol challenge with M. tuberculosis, bacillary load in the lungs
and spleen of guinea pigs was determined. In experiment (Exp)-I,
guinea pigs were infected with M. tuberculosis 6 weeks post-
immunization and were euthanized at 10 weeks post-infection.
Immunization with both BCG as well as with rBCG85C resulted
in a marked reduction in the lung and spleen bacillary load, when
compared to the saline treatment (Fig. 1A). However, the extent of
reduction in case of rBCG85C immunized guinea pigs was
significantly greater, when compared to BCG immunized animals
(by 1.87 log10 in lung, p,0.01 and by 2.36 log10 in spleen,
p,0.001). In a subsequent study (Exp-II), wherein guinea pigs
were infected 12 weeks post-immunization and euthanized at 16
weeks post-infection, BCG vaccination exhibited a considerable
decline in its ability to impede bacillary multiplication, as was
evident from a comparable bacillary count in BCG and saline
treated animals. However, bacillary load in rBCG85C-immunized
Figure 1. Superior protection by rBCG85C vaccination against
M. tuberculosis challenge. The figure depicts the bacillary load in the
lungs and spleen of immunized and saline treated guinea pigs (n=6) at
(A) 10 weeks (Exp-I) and (B) 16 weeks (Exp-II) post-infection.
Immunization with rBCG85C resulted in a significantly lower bacillary
load in lung and spleen, when compared to both BCG and saline
groups. Each point represents the Log10 CFU value for an individual
animal and the bar depicts mean (6SE) for each group. The lower limit
of detection was 1.0 log10 CFU/g of tissue and animals with
undetectable bacilli were allotted a CFU value of 1.0 log10/g. Missing
data points represent the animals that succumbed to disease before the
time of euthanasia. *, p,0.05; **, p,0.01 and ***, p,0.001 (One way
ANOVA).
doi:10.1371/journal.pone.0003869.g001
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immunized animals (by 0.87 log10 in lung, p,0.05 and by 1.99
log10 in spleen, p,0.05) (Fig. 1B). These observations clearly
indicated enhanced protective efficacy of rBCG85C, when
compared to BCG.
Influence of rBCG85C vaccination on gross pathology
The trend in lung and spleen bacillary load was also
substantiated by the gross pathological changes. At 10 weeks
post-infection (Exp-I), severe pathological damage was observed in
case of saline treated animals characterized by extensive
involvement and numerous large tubercles with scattered areas
of necrosis in both lung and liver (Fig. 2A). In addition, a marked
enlargement of spleen with numerous large and small sized
tubercles with occasional attrition of capsular structure was also
observed in most of the saline treated animals. Guinea pigs
immunized with BCG or rBCG85C showed a significant
reduction in gross pathological damage, when compared to the
saline treated animals. However, lesions were predominantly
scanty and extremely small in the organs of rBCG85C-immunized
animals, when compared to the BCG immunized animals
(p,0.01) (Fig. 2A). At 16 weeks post-infection (Exp-II), 50% of
the saline treated animals succumbed to the disease (3/6); animals
that survived showed characteristic signs of end stage TB with
extensive pathological damage (Fig. 2B). Although, the number of
animals that survived until the time of euthanasia was similar in
both the vaccinated groups (4/6), surviving animals in the BCG
group showed extensive pulmonary damage with several large and
small size tubercles distributed throughout the lung, together with
progressive splenic and hepatic tissue destruction comparable to
that observed in saline treated animals. However, animals
immunized with rBCG85C showed a significantly reduced gross
pathological damage, when compared to saline treated animals
(p,0.05), as was evident from minimal involvement of the lungs
with no evident sign of tissue damage in both liver and spleen
(Fig. 2B).
rBCG85C vaccination reduces granulomatous
inflammation
To evaluate the histopathological changes in the lungs and liver
of immunized and saline treated animals, the tissue sections were
stained with haematoxylin and eosin and granuloma percent was
measured as described in the materials and methods. At 10 weeks
post-infection, the type of lesions observed in the lungs of saline
treated guinea pigs typically represented an advanced stage
granuloma, with extensive coalescence of multiple granulomas
covering 65% area of the lung sections (Fig. 3A). The lung
granulomas in this group were characterized by extensive necrosis
resulting in the loss of lung micro-architecture. The extent of
granulomatous infiltration in BCG vaccinated animals was
comparable to that observed in case of saline treated animals
(Fig. 3A). However, the extent of necrosis in BCG vaccinated
animals was relatively less, when compared to the saline treated
animals. Immunization with rBCG85C resulted in a significant
reduction in the granulomatous infiltration (8%), with the presence
of very few small and discrete granulomas, when compared to the
saline treated animals (p,0.01). The alveolar and bronchiolar
structures in the surrounding areas were well preserved in this
group. On comparing the pathological changes in liver (Fig. 3A),
BCG immunized animals showed a relatively less granulomatous
infiltration (12%), when compared to the saline treated animals
(25%). However, vaccination with rBCG85C prevented hepatic
damage as was evident from only a negligible (0–2%) granuloma-
tous infiltration, when compared to BCG immunized animals
(p,0.01).
At 16 weeks post-infection (Exp-II), the saline treated animals
exhibited extensive granulomatous infiltration with coalescing
necrotic granulomas (75%) effacing the pulmonary parenchyma
Figure 2. Reduction in gross pathological lesions in rBCG85C vaccinated animals following M. tuberculosis infection. The figure depicts
representative photographs of lungs, liver and spleen of vaccinated and saline treated animals (n=6) euthanized at (A) 10 weeks (Exp-I) and (B) 16
weeks (Exp-II) post-infection. Based on the extent of involvement, number and size of tubercles, areas of inflammation and necrosis, gross
pathological scores were graded from 1–4 (Table S1) and represented graphically. Each point represents score for an individual animal and the bar
depicts median (6inter quartile range) for each group. Missing data points represent the animals that succumbed to disease before the time of
euthanasia. Immunization with rBCG85C resulted in fewer and smaller pulmonary, hepatic and splenic lesions when compared to both BCG and
saline group. *, p,0.05 and **, p,0.01 (Mann-Whitney U test).
doi:10.1371/journal.pone.0003869.g002
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animals also represented a scenario similar to that observed in the
saline treated animals showing 66% granulomatous infiltration. In
contrast, immunization with rBCG85C preserved the pulmonary
tissue organization with a significant reduction in pathological
damage (16% granuloma, p,0.05) and necrosis. On comparing
the pathological changes in liver (Fig. 3B), saline treated animals
exhibited extensive granulomatous infiltration in the hepatic
lobules, showing multiple coalescing foci of necrotic granulomas
(43%). The reduction in hepatic damage in case of BCG
immunization was variable, with percent granuloma ranging from
15–60%. Immunization with rBCG85C resulted in a significant
reduction in hepatic damage with only a negligible granulomatous
infiltration (3.5%, p,0.05).
Reduction in pulmonary fibrosis with rBCG85C
vaccination
Development of necrosis and eventual fibrosis resulting in
irreversible effacement of lung micro-architecture and respiratory
failure are the primary features of progressive pulmonary TB in
guinea pig model [33,34]. Hence, in addition to the measurement
of percent granuloma, the extent of collagen deposition was also
determined. In case of saline treated animals at 10 weeks post-
infection (Exp-I), extensive areas of collagen deposition in and
around the granulomas were observed (Fig. 4A). Apart from the
presence of collagen surrounding the necrotized core, irregular
thick bands with a large number of foamy macrophages entrapped
within the collagenous layer were also observed. However, a
marked reduction in collagen deposition was observed in case of
BCG immunized animals (p,0.05), wherein, the thin and diffused
bands of collagen were primarily restricted to the periphery of
granulomatous areas (Fig. 4A). Commensurate with the reduced
granulomatous inflammation, lung sections derived from
rBCG85C-immunized animals exhibited the presence of only a
negligible amount of collagen. In Exp-II, paralleling the increase
in granulomatous response observed at 16 weeks post-infection, a
marked increase in collagen deposition was observed in the case of
BCG as well as saline treated animals (Fig. 4B). However,
rBCG85C immunized guinea pigs showed only a negligible
collagen staining, when compared to both the control groups
(p,0.05).
Decline in the antigen load in pulmonary granulomas
following rBCG85C vaccination
To assess the effect of vaccination on clearance of antigen
depots and/or bacillary remnants (a source of inflammation), IHC
staining for M. tuberculosis antigens was carried out. Since, Ag85
complex proteins represent some of the predominant antigens
localized both in the bacterial cell wall as well as in the secretory
fraction, antibodies specific to Ag85 complex proteins were
employed for in situ localization of these antigens as a marker for
the presence of both live mycobacteria and mycobacterial
Figure 3. Histopathological changes in the lungs and liver of rBCG85C vaccinated animals following M. tuberculosis challenge. The
figure depicts representative lower magnification photomicrographs of H&E stained, formalin fixed and paraffin embedded 5 mm sections of lung
and liver of guinea pigs (n=6) euthanized at (A) 10 weeks (Exp-I) and (B) 16 weeks (Exp-II) post-infection. Saline group is characterized by the
presence of multiple coalescing granulomas with central necrotic core. rBCG85C immunized animals showed reduced granulomatous infiltration with
only a few small and discrete granulomas in comparison to BCG vaccinated animals. Pulmonary and hepatic granuloma percent were measured and
graphically represented by box plot, wherein median values are denoted by horizontal line, the mean is represented by ‘+’, inter quartile range by
boxes, and the maximum and minimum values by whiskers. *, p,0.05 and **, p,0.01 (Mann-Whitney U test).
doi:10.1371/journal.pone.0003869.g003
rBCG85C Protects against TB
PLoS ONE | www.plosone.org 5 December 2008 | Volume 3 | Issue 12 | e3869remnants in the pulmonary granulomas. Immuno-localization
provides advantage over acid fast staining, as the later requires the
presence of intact cell wall of the bacilli, in contrast IHC can detect
bacillary remnants, secreted antigens as well as the live bacilli. A
reduced bacillary load and granulomatous inflammation in the
lungs of rBCG85C-immunized animals suggested a commensurate
clearance of antigenic depots from the pulmonary granulomas. On
comparing the extent of antigen staining, extensive areas of intense
staining within the granulomas were observed in the saline treated
animals at 10 weeks post-infection (Fig. 5A). However, lung
sections derived from animals vaccinated with BCG and
rBCG85C showed a significantly reduced antigen load, when
compared to the saline treated animals (p,0.05). On extending the
time of euthanasia to 16 weeks, animals immunized with
rBCG85C showed a significant reduction in antigen load in
comparison to BCG immunized animals (p,0.05), with the latter
exhibiting a staining pattern comparable to that observed in saline
treated animals (Fig. 5B).
Immuno-localization of IFN-c and TNF-a in pulmonary
granulomas
Immuno-histochemical staining of the lung tissues showed the
presence of IFN-c and TNF-a in all the groups and was marked by
their abundance in the granulomatous lesions compared to that in
the non-granulomatous areas. However, the extent of staining
varied among the groups. In Exp-I, based on the area and
intensity of staining, the extent of IFN-c expression in granulo-
matous regions indicated a comparable presence of this cytokine in
the lungs of BCG and rBCG85C immunized animals at 10 weeks
post-infection (Fig. 6A). Majority of the saline treated animals
showed relatively very low levels of this cytokine localized
primarily in the areas infiltrated with macrophages. Lung sections
from BCG immunized animals showed moderate levels of IFN-c
staining in the areas infiltrated by both macrophages and
lymphocytes. A similar pattern of IFN-c staining was also observed
in case of rBCG85C-immunized animals (Fig. 6A). At this time
point, a very high level of TNF-a was observed in case of saline
treated animals (Fig. 7A). TNF-a was localized extensively in the
necrotic areas as well as in the macrophages and extra cellular
spaces within the advanced coalescent granulomas. Immunization
with BCG resulted in the reduced amounts of TNF-a expression
primarily localized inside the macrophages and in non-necrotic
granulomatous areas. In contrast, rBCG85C-vaccinated animals
showed only a negligible staining for TNF-a with its presence
restricted primarily to the granuloma core (Fig. 7A). On extending
the time of euthanasia to 16 weeks in Exp-II, an overall reduced
IFN-c levels were observed in all the groups with no significant
differences (Fig. 6B). As observed at 10 weeks, at this time point
also, the levels of TNF-a were found to be significantly lower in
case of both the vaccinated groups, when compared to the saline
treated animals (p,0.05) (Fig. 7B)
Modulation of host gene expression in the lungs by
rBCG85C vaccination
Profiling of various cytokines and iNOS by real time RT-PCR
using gene specific primers (Table S2) and RNA isolated from the
lungs of vaccinated and non-vaccinated guinea pigs revealed a
distinct pattern of IFN-c, TNF-a, TGF-b, IL-12 and iNOS
expression at both 10 weeks and 16 weeks post M. tuberculosis
infection. The data for real time PCR is graphically shown in Fig. 8
as % fold induction in the levels of different cytokines and iNOS
relative to the induction in the uninfected (and non-vaccinated)
animals. The relative proportion of IFN-c and TNF-a in the
transcript pool obtained from the whole lung homogenate was
found to be in striking contrast to the results obtained from
immuno-localization of these cytokines by IHC. At 10 weeks post-
infection (Exp-I), both vaccinated and saline treated guinea pigs
showed a comparable fold induction of these cytokines at mRNA
level (Fig. 8A). However, at 16 weeks post-infection (Exp-II), a
significant up-regulation of both the inflammatory cytokines (IFN-
c and TNF-a) was observed in BCG immunized guinea pigs
(Fig. 8B), when compared to the saline treated animals (p,0.001).
In case of rBCG85C-immunized animals, a significant reduction
in the bacillary load and pathological damage was accompanied
by a marked reduction in the inflammatory responses as was
evident from the reduced transcript levels of these cytokines, when
Figure 4. Influence of rBCG85C vaccination on pulmonary fibrosis. The representative photomicrographs of Van Gieson stained 5 mm lung
sections of guinea pigs (n=4) euthanized at (A) 10 weeks (Exp-I) and (B) 16 weeks (Exp-II) post-infection, depict significantly less collagen deposition
(red color) in association with reduced granulomatous inflammation in rBCG85C immunized animals, when compared to BCG vaccinated group.
Saline group is characterized by extensive fibrosis of granulomatous regions. Scale bar represents 1000 mm. Extent (Q) of pulmonary fibrosis was
measured [Q=Intensity (I)6area (A) of staining] and represented graphically as median (6inter quartile range). *, p,0.05 (Mann-Whitney U test).
doi:10.1371/journal.pone.0003869.g004
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rBCG85C immunized animals showed marginally higher levels of
TNF-a in comparison to the saline treated animals, the IFN-c
levels in both the groups remained comparable (Fig. 8B).
Surprisingly, in the saline group, despite a very high bacillary
load and extensive pulmonary tissue damage, very low levels of
IFN-c and TNF-a were observed at both the time points, which
was in striking contrast to relatively very high levels of TNF-a
staining observed in pulmonary granulomas in this group by IHC.
In addition to these two major cytokines (IFN-c and TNF-a)
that have been implicated in TB associated pathology, the
combinatorial effect of IL-12p40 (pro-inflammatory) and TGF-b.
(anti-inflammatory) on granuloma formation, tissue remodeling
and disease resolution was also studied by measuring the
Figure 5. Reduced M. tuberculosis antigen load in pulmonary granulomas of rBCG85C vaccinated animals. The representative
photomicrographs of 5 mm lung sections show immuno-histochemical staining (brown color) for Ag85 complex proteins in pulmonary granulomas at
(A) 10 weeks (Exp-I) and (B) 16 weeks (Exp-II) post-infection. Immunization with rBCG85C in conjunction with reduced granulomatous inflammation
showed a significantly lower antigen load at both 10 and 16 weeks post-infection, when compared to saline treated animals, which showed extensive
staining surrounding and within the necrotic areas. BCG vaccination showed a significant reduction in antigen load at 10 weeks post-infection. At 16
weeks post-infection, extensive staining was observed in BCG immunized animals similar to that in case of saline-treated animals. Scale bar represents
1000 mm. Extent (Q) of staining was measured [Q=intensity (I)6area (A) of staining] and represented graphically as median (6inter quartile range). *,
p,0.05 (Mann-Whitney U test).
doi:10.1371/journal.pone.0003869.g005
Figure 6. Immuno-localization of IFN-c in pulmonary granulomas. The representative photomicrographs of 5 mm lung sections show
immuno-histochemical staining (brown color) for IFN-c in pulmonary granulomas at (A) 10 weeks (Exp-I) and (B) 16 weeks (Exp-II) post-infection. IFN-c
staining in both the vaccinated groups was found to be relatively higher at 10 weeks post-infection in comparison to the saline treated group.
However, at 16 weeks post-infection, a comparable staining was observed in both the vaccinated and saline treated animals. Scale bar represents
200 mm. Extent (Q) of staining was measured [Q=Intensity (I)6area (A) of staining] and represented graphically as median (6inter quartile range).
(Mann-Whitney U test).
doi:10.1371/journal.pone.0003869.g006
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PLoS ONE | www.plosone.org 7 December 2008 | Volume 3 | Issue 12 | e3869Figure 7. Immuno-localization of TNF-a in pulmonary granulomas. The representative photomicrographs of 5 mm lung sections show
immuno-histochemical staining (brown color) for TNF-a in pulmonary granulomas at (A) 10 weeks (Exp-I) and (B) 16 weeks (Exp-II) post-infection.
Immunization with rBCG85C in conjunction with reduced granulomatous inflammation showed a significantly reduced staining for TNF-a at both 10
and 16 weeks post-infection, when compared to saline treated animals, which showed extensive staining surrounding and within the necrotic areas.
The extent of staining in BCG group was relatively higher at 10 weeks in comparison to rBCG85C, however, at 16 weeks a comparable staining was
observed. Scale bar represents 200 mm. Extent (Q) of staining was measured [Q=intensity (I)6area (A) of staining] and represented graphically as
median (6inter quartile range). *, p,0.05 (Mann-Whitney U test).
doi:10.1371/journal.pone.0003869.g007
Figure 8. Modulation of host gene expression in the lung by rBCG85C vaccination. Expression of various cytokines and iNOS was
measured in the lung tissues of vaccinated and saline treated guinea pigs (n=3) at (A) 10 weeks (Exp-I) and (B) 16 weeks (Exp-II) post-infection by
semi-quantitative real time RT-PCR using gene specific primers (Table S2). The data were normalized to 18S rRNA levels and then normalized to the
values of uninfected animals to obtain DDCt values. The % fold induction values were measured (2
2DDCt6100) and are graphically represented as
mean (6SE). Immunization with rBCG85C resulted in relatively lower levels of pro-inflammatory cytokines IL-12, IFN-c and TNF-a and moderate level
of anti-inflammatory cytokine TGF-b with a significant up-regulation of iNOS expression, when compared to both BCG immunized and saline treated
animals. *, p,0.05; **, p,0.01 and ***, p,0.001 (One way ANOVA).
doi:10.1371/journal.pone.0003869.g008
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tuberculosis infection, BCG immunized guinea pigs showed
relatively higher levels of IL-12p40, when compared to saline
treated animals (Fig. 8A). Immunization with rBCG85C resulted
in only a marginal augmentation in the expression levels of IL-
12p40 over saline treatment. With progression of disease to 16
weeks (Fig. 8B), a marked shift in the expression profile of this
cytokine was observed, wherein, rBCG85C immunized animals
showed a considerable reduction in the levels of IL-12p40, when
compared to saline treated animals (p,0.001). However, there was
a significant up-regulation of this cytokine in BCG immunized
guinea pigs, when compared to the saline group (p,0.001).
On comparing the expression levels of TGF-b, at 10 weeks post-
infection (Fig. 8A), no considerable differences were observed in
the vaccinated and saline treated animals. However, at 16 weeks
post-infection (Fig. 8B), both BCG and rBCG85C immunized
animals showed increased levels of TGF-b, when compared to the
saline treated animals. The extent of up-regulation of TGF-b in
BCG group was significantly higher in comparison to rBCG85C-
immunized animals (p,0.01).
Production of highly reactive nitric oxide intermediates (RNI)
represents one of the key mycobactericidal mechanisms employed
by the activated macrophages and iNOS is the principal enzyme
involved in the generation of RNI by phagocytes [35,36]. Hence,
in addition to studying the effect of vaccination on induction of
various cytokines, expression of iNOS was also measured. On
comparing the transcription profile of iNOS in lungs obtained
from various vaccination groups, at 10 weeks post-infection,
despite the significant differences in bacillary load and pathological
damage, no significant differences in the levels of iNOS were
observed between the vaccinated and non-vaccinated animals
(Fig. 8A). However, at 16 weeks, distinct differences in the levels of
iNOS expression were observed among various groups (Fig. 8B).
Immunization with both BCG and rBCG85C resulted in a
marked elevation in iNOS levels in comparison to the saline
treatment (p,0.001). However, the extent of up-regulation was
significantly higher in rBCG85C group in comparison to BCG
immunized animals (p,0.001), which corroborate well with the
differences in the bacillary load observed among these groups at
this time point.
Discussion
This study demonstrates a significant enhancement in the
protective efficacy of BCG by over expression of Ag85C- an
immuno-dominant antigen of M. tuberculosis and correlation of this
superior protection with the immuno-pathological events attribut-
able to modulation of the cytokine profile of pulmonary
granulomas. The parameters used for the evaluation of protective
efficacy following an aerosol challenge with M. tuberculosis were, (i)
bacillary load in lung and spleen and (ii) pathological changes in
lung, liver and spleen. The challenge dose employed in this study
resulted in an early manifestation of severe disease symptoms and
thus allowed discrimination between the protective efficacies of
rBCG and parent BCG vaccines within a reasonable time frame.
At 10 weeks post-infection, vaccination with rBCG85C resulted in
a significantly reduced bacillary load in the lungs (,87 folds) along
with a marked reduction in hematogenous spread to the spleen
(,360 folds) in comparison to vaccination with the parental BCG
strain. This reduced bacillary load was also accompanied by a
marked reduction in the pulmonary, splenic and hepatic
pathology. On extending the interval between vaccination and
challenge (to 12 weeks) and between challenge and euthanasia (to
16 weeks), rBCG85C continued to impart a relatively superior
protection with a remarkably greater control on bacillary
multiplication in the lungs (,9 folds) and a successful restriction
of the hematogenous spread of tubercle bacilli to spleen (,100
folds) in comparison to immunization with the parent BCG strain.
The importance of these variables was clearly emphasized in a
comprehensive study carried out by EU TB Vaccine Cluster,
wherein, the superiority of many candidate vaccines over BCG
was demonstrated by employing a high dose of challenge with an
extended post challenge evaluation period [37].
Being a localized infection, the control of pulmonary TB largely
depends on the orchestration of various cellular components of the
immune system and a coordinated interplay of various pro- and
anti-inflammatory cytokines at the foci of infection [38,39].
Several studies have suggested that often it requires more than a
single cytokine to influence the cell mediated tissue damage in
response to microbial infection and a fine-tuning of multiple
cytokines is de rigueur for an effective clearance of the pathogen
[39,40]. In the absence of vaccination, the clinical manifestation of
progressive end-stage TB in guinea pigs is known to be associated
with a strong inflammatory response to the persistent antigens or
bacilli leading to extensive necrosis and progressive fibrosis [33].
However, an efficient vaccine is expected to prime the immune
system to generate an efficiently regulated and targeted response
for an effective microbial and antigenic clearance, minimizing the
collateral damage to the host. Immuno-localization of Ag85
complex proteins–some of the most abundant proteins of M.
tuberculosis, as a marker of the mycobacterial antigen load, showed
elevated levels of these antigens in the granulomas as observed in
case of saline treated animals. This increased antigen load was
found to be associated with the production of superfluous amount
of TNF-a, unwarranted inflammation, tissue destruction and
excessive collagen deposition. However, in addition to the
bacillary clearance, rBCG85C mediated immune responses
resulted in reduced antigen load indicating an effective removal
of mycobacterial antigens and/or the bacillary remnants. A
corresponding reduction in the extent of granulomatous inflam-
mation and fibrosis in this group further substantiated the fact that
an effective removal of the residual antigenic depots from the sites
of infection is essential for the resolution of granulomatous lesions.
More over, reduction in the levels of IFN-c and TNF-a, towards
the later stage of disease in case of the rBCG85C-immunized
animals, further signifies the fact that, although, induction of these
cytokines following M. tuberculosis infection is known to be essential
for the initial containment of the bacilli [39,41], a subsequent
reduction in the levels of these cytokines is crucial for the
resolution of granulomatous lesions, as observed in this study.
However, an apparent lack of concordance in the levels of these
cytokines (as measured by IHC) with the antigen load and
granulomatous inflammation in the lungs of BCG immunized
animals suggests involvement of additional cytokines and cellular
components in the pulmonary inflammation and tissue damage
not measured in this study.
Comparison of mRNA expression profile for various cytokines
showed that at 10 weeks post-infection, no specific pattern was
evident for any vaccine regimen. However, at 16 weeks a
characteristic cytokine profile was found to be associated with
the history of vaccination. BCG immunization caused up-
regulation of both the pro-inflammatory cytokines (IL-12, IFN-c
and TNF-a) as well as anti-inflammatory cytokine (TGF-b). These
counter-acting mechanisms could neither reduce the exaggerated
granulomatous response, nor control excessive bacillary multipli-
cation. In contrast, rBCG85C immunization resulted in signifi-
cantly lowered levels of IL-12, IFN-c and TNF-a and a marginal
decline in the levels of TGF-b in comparison to BCG vaccination.
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been reported to be essential for the resolution of granulomatous
inflammation and thus crucial for alleviation of disease symptoms
(reviewed in [42]). Besides, the up-regulation of iNOS in case of
rBCG85C vaccination towards the later stage of the disease,
possibly resulted in an efficient killing of the bacilli, in comparison
to the BCG vaccinated animals. Such mycobactericidal effect of
iNOS although has been reported in several in vitro and in vivo
studies [36,43,44], its influence in the context of vaccine response
in guinea pig model for such a prolonged period has been
investigated for the first time in this study.
In all TB vaccine related studies, BCG has been used as the gold
standard to pronounce the worthiness of a new vaccine candidate,
because it is the failure of BCG in the adult human population that
has necessitated the development of a new TB vaccine in the first
place. However, this convention suffers from a caveat–a new
vaccine is required for protection in humans, wherein, BCG does
not work well; on the other hand, a new vaccine cannot progress to
human trials without proving its superiority to BCG in animal
models in which BCG works rather efficiently. Hence, it has been
difficult to develop vaccines, which would ensure a superior
protection over BCG in animal models. It is thus not surprising
that in spite of a large number of vaccine related studies, merely 9
vaccine regimens have progressed to various stages of human
clinical trials (reviewed in [45]). These vaccines have shown a
better or equal performance in comparison to BCG in their ability
(i) to reduce the bacillary load in lung and spleen and/or (ii) to
reduce pathological damage and/or (iii) to perform better in time
to death assay. While survival assay represents the most
dependable tool to evaluate the protective efficacy of TB vaccines
in animal models, due to infrastructure and time constraints
involved in these long drawn studies, it has been customary to first
evaluate TB vaccines in time-bound studies and then channelize
the promising ones through survival assays [37,46]. We have not
yet carried out the survival assays with the rBCG85C vaccine
however, the 16 weeks assay carried out to evaluate its protective
efficacy in a highly relevant guinea pig model of TB shows that at
least on the basis of such evaluations and their comparison with all
the vaccines that have already progressed to clinical trials,
rBCG85C imparts a remarkable protection. The enduring
protection observed in this study gives enough reasons to postulate
that if an open-ended study is carried out, rBCG85C vaccine in all
likelihood would show enhanced survival of guinea pigs.
Furthermore, we have attempted to provide an insight into the
association between the protective efficacy imparted by an efficient
vaccine and the cytokine milieu in the pulmonary granuloma in
guinea pigs for such a prolonged post-challenge period. Such a
comprehensive evaluation of the temporal and spatial variations in
immune components, if carried out along with the long-term
survival assays, may help in removing the existing paradox
associated with the role of various cellular components and
cytokines in mediating protection against M. tuberculosis infection.
Our future efforts would focus on these aspects.
Supporting Information
Table S1 Post-mortem gross pathological scoring system. The
table illustrates the gross pathological scoring system used for
visual scoring of lesions in lung, liver and spleen of guinea pigs
infected with M. tuberculosis. Mitchison’s virulence scoring system
was modified and equal emphasis was given to every organ and
scores were graded as 1–4.
Found at: doi:10.1371/journal.pone.0003869.s001 (0.04 MB
DOC)
Table S2 Primer sequences used for real time PCR.
Found at: doi:10.1371/journal.pone.0003869.s002 (0.03 MB
DOC)
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